Consistently, using percentage of CK19(+) area as a second approach for measuring tumor burden, PD901 treatment led to tumor shrinkage, with combined PD901/MLN0128 therapy not providing further benefit (Fig. 5b). Here, KRT19 is linked to neoplasm.